FY 2006 appropriation for effectiveness research
House/Labor, HHS & Education Subcommittee mark for fiscal 2006 appropriations budgets $15 mil. for AHRQ to perform comparative effectiveness research. AHRQ received $15 mil. for the program in FY 2005 (1"The Pink Sheet" Sept. 20, 2004, p. 14)...
You may also be interested in...
Funding for prescription drug comparative effectiveness research is included in the HHS fiscal year 2005 appropriations bill reported to the full Senate Sept. 15
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.